First pass effect

Route 92 Medical® Announces Publication of Initial SUMMIT NZ Clinical Trial Results Demonstrating 80% First Pass Effect with the 088 Monopoint® Operating Platform

Retrieved on: 
Monday, June 6, 2022
List of highways numbered 92, MCA, Stroke, Journal, Safety, Doctor of Philosophy, Â, Medicine, Solution, Physician, ID, Disability, GLOBE, Patient, Thrombectomy, Journal of NeuroInterventional Surgery, First pass effect, U.S. FDA, Diagnosis, SAN, MD, Clinical trial, Death, Auckland City Hospital, M1, Pharmaceutical industry, Medical imaging

SAN MATEO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a private medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the publication of initial results of the SUMMIT NZ clinical trial, a single-arm, multi-center, prospective trial evaluating the proprietary Monopoint operating platform.

Key Points: 
  • SAN MATEO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a private medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the publication of initial results of the SUMMIT NZ clinical trial, a single-arm, multi-center, prospective trial evaluating the proprietary Monopoint operating platform.
  • The Route 92 HiPoint 88 aspiration catheter successfully reached the proximal MCA (M1 segment) in 100% of the cases attempted.
  • The platform is designed to improve catheter deliverability offering the advantage of greater simplicity for the operating physician to efficiently perform thrombectomy for patients.
  • The trial evaluated the safety and clinical efficacy of the novel Monopoint operating platform in delivering the super-bore and large-bore HiPoint aspiration catheters (0.088in ID and 0.070in ID) to the M1.

Liquid CORE® Gum Company releases FLATLINER™, the World's Strongest Caffeinated Performance Gum

Retrieved on: 
Thursday, February 24, 2022
Zero, Earth's outer core, Pharmacology, Ministry of Health & Wellness, NIH, Memorial Day, Digestion, Taste, Red Bull, Performance, Caffeine, Xylitol, Brain Boost, First pass effect, Monster, Rock Star, Wellness, Liquid, Time, Gum arabic

DENVER, Feb. 24, 2022 /PRNewswire/ --Liquid CORE Gum Company ("Liquid CORE") announced the release of FLATLINER Gum this week, a gum that showcases the effectiveness of its liquid center functional delivery system.Each piece of FLATLINER contains 130mg of natural caffeine, whereas the strongest previously available gums top out at 100mg.

Key Points: 
  • DENVER, Feb. 24, 2022 /PRNewswire/ --Liquid CORE Gum Company ("Liquid CORE") announced the release of FLATLINER Gum this week, a gum that showcases the effectiveness of its liquid center functional delivery system.Each piece of FLATLINER contains 130mg of natural caffeine, whereas the strongest previously available gums top out at 100mg.
  • This dynamic interaction among the functional ingredients and flavors is unique to all Liquid CORE Gum Company gums.
  • "We are excited about FLATLINER.It has the elements to highlight our Liquid CORE Gum technology while 'waking up' the consumer to the performance benefits of chewing functional gum," said Liquid CORE Founder & CEO Troy Widgery.
  • About:Liquid CORE Gum Company manufactures liquid center functional Performance, Health & Wellness chewing gums at their factory in Denver, Colorado USA.

Why Transdermal Drug Delivery Systems are Outweighing Advantages of Traditional Methods

Retrieved on: 
Tuesday, December 15, 2020
Health sciences, Pharmacology, Life sciences, Routes of administration, Medicinal chemistry, Dosage forms, Pharmacokinetics, Transdermal patch, Bioavailability, First pass effect, Transdermal, Drug delivery

Transdermal delivery has benefit of simple application and may be a good alternative to oral delivery in cases when orally administrated drug causes serious side effects.

Key Points: 
  • Transdermal delivery has benefit of simple application and may be a good alternative to oral delivery in cases when orally administrated drug causes serious side effects.
  • A recent report form Adriot Market Research said that the global transdermal drug delivery system market is projected to reach USD $8,117 million by 2028, growing at a CAGR of 4.7%.
  • Enhancing bioavailability via bypassing first pass metabolism, improving tolerability and dosing, minimizing pharmaco-kinetic peaks and troughs and increasing patient compliance in continuous delivery are some of the factors driving the growth of the global transdermal drug delivery system (TDDS) market.
  • Moreover, itching, and local edema can be caused by the drug, the adhesive, or other excipients in the patch formulation may hinder the market growth."

Why Transdermal Drug Delivery Systems are Outweighing Advantages of Traditional Methods

Retrieved on: 
Tuesday, December 15, 2020
Health sciences, Pharmacology, Life sciences, Routes of administration, Medicinal chemistry, Dosage forms, Pharmacokinetics, Transdermal patch, Bioavailability, First pass effect, Transdermal, Drug delivery

Transdermal delivery has benefit of simple application and may be a good alternative to oral delivery in cases when orally administrated drug causes serious side effects.

Key Points: 
  • Transdermal delivery has benefit of simple application and may be a good alternative to oral delivery in cases when orally administrated drug causes serious side effects.
  • A recent report form Adriot Market Research said that the global transdermal drug delivery system market is projected to reach USD $8,117 million by 2028, growing at a CAGR of 4.7%.
  • Enhancing bioavailability via bypassing first pass metabolism, improving tolerability and dosing, minimizing pharmaco-kinetic peaks and troughs and increasing patient compliance in continuous delivery are some of the factors driving the growth of the global transdermal drug delivery system (TDDS) market.
  • Moreover, itching, and local edema can be caused by the drug, the adhesive, or other excipients in the patch formulation may hinder the market growth."

IntelGenx and Cybin Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film

Retrieved on: 
Tuesday, July 7, 2020
Medicinal chemistry, Health sciences, Pharmacology, Pharmaceutical sciences, Pharmacokinetics, Dosage forms, Organophosphates, Entheogens, Bioavailability, Psilocybin, First pass effect, Thin-film drug delivery

We are looking forward to working with Cybin to realize these potential benefits for patients struggling with mental health disorders.

Key Points: 
  • We are looking forward to working with Cybin to realize these potential benefits for patients struggling with mental health disorders.
  • We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film, said Cybins Chief Medical Officer, Dr. Jukka Karjalainen.
  • Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver, the systemic bioavailability of orally-dissolving psilocybin film is expected to be quite high.
  • In addition, the dose of psilocybin administered by an orally-dissolving film is expected to be a fraction of what is required in oral capsules.

Cybin Corp. and IntelGenx Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film

Retrieved on: 
Tuesday, July 7, 2020
Alternative medicine, Mental health, Health, Other Health, Pharmaceutical, Biotechnology, Medicinal chemistry, Chemistry, Health sciences, Natural sciences, Pharmacokinetics, Entheogens, Bioavailability, Psilocybin, First pass effect, Cybin, IntelGenx

We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film, said Cybins Chief Medical Officer, Dr. Jukka Karjalainen.

Key Points: 
  • We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film, said Cybins Chief Medical Officer, Dr. Jukka Karjalainen.
  • Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver, the systemic bioavailability of orally-dissolving psilocybin film is expected to be quite high.
  • In addition, the dose of psilocybin administered by an orally-dissolving film is expected to be a fraction of what is required in oral capsules.
  • Taken together, these features have the potential to increase both the safety and efficacy of psilocybin when administered in this manner.